Show simple item record

dc.contributor.authorGhosh, Jagadish C.
dc.contributor.authorDohi, Takehiko
dc.contributor.authorRaskett, Christopher M.
dc.contributor.authorKowalik, Timothy F.
dc.contributor.authorAltieri, Dario C.
dc.date2022-08-11T08:09:50.000
dc.date.accessioned2022-08-23T16:45:09Z
dc.date.available2022-08-23T16:45:09Z
dc.date.issued2006-12-21
dc.date.submitted2008-06-18
dc.identifier.citationCancer Res. 2006 Dec 15;66(24):11576-9. <a href="http://dx.doi.org/10.1158/0008-5472.CAN-06-3095">Link to article on publisher's site</a>
dc.identifier.issn0008-5472 (Print)
dc.identifier.doi10.1158/0008-5472.CAN-06-3095
dc.identifier.pmid17178848
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40625
dc.description.abstractTumor cells often become resistant to DNA damage-based therapy; however, the underlying mechanisms are not yet understood. Here, we show that tumor cells exposed to DNA damage counteract cell death by releasing the antiapoptotic protein, survivin, from mitochondria. This is independent of p53, and requires activated checkpoint kinase 2 (Chk2), a putative tumor suppressor. Molecular or genetic targeting of Chk2 prevents the release of survivin from mitochondria, enhances DNA damage-induced tumor cell apoptosis, and inhibits the growth of resistant in vivo tumors. Therefore, activated Chk2 circumvents its own tumor-suppressive functions by promoting tumor cell survival. Inhibiting Chk2 in combination with DNA-damaging agents may provide a rational approach for treating resistant tumors.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17178848&dopt=Abstract">Link to article in PubMed</a>
dc.subjectAdenocarcinoma
dc.subjectAnimals
dc.subjectApoptosis
dc.subjectBreast Neoplasms
dc.subjectCell Line, Tumor
dc.subjectCell Survival
dc.subjectColonic Neoplasms
dc.subject*DNA Damage
dc.subjectEnzyme Activation
dc.subjectFemale
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectHumans
dc.subjectMale
dc.subjectMice
dc.subjectMice, SCID
dc.subjectProstatic Neoplasms
dc.subjectProtein-Serine-Threonine Kinases
dc.subjectRNA, Small Interfering
dc.subjectTransfection
dc.subjectTransplantation, Heterologous
dc.subjectCancer Biology
dc.subjectMicrobiology
dc.subjectMolecular Genetics
dc.titleActivated checkpoint kinase 2 provides a survival signal for tumor cells
dc.typeJournal Article
dc.source.journaltitleCancer research
dc.source.volume66
dc.source.issue24
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=1342&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/343
dc.identifier.contextkey533051
refterms.dateFOA2022-08-23T16:45:09Z
html.description.abstract<p>Tumor cells often become resistant to DNA damage-based therapy; however, the underlying mechanisms are not yet understood. Here, we show that tumor cells exposed to DNA damage counteract cell death by releasing the antiapoptotic protein, survivin, from mitochondria. This is independent of p53, and requires activated checkpoint kinase 2 (Chk2), a putative tumor suppressor. Molecular or genetic targeting of Chk2 prevents the release of survivin from mitochondria, enhances DNA damage-induced tumor cell apoptosis, and inhibits the growth of resistant in vivo tumors. Therefore, activated Chk2 circumvents its own tumor-suppressive functions by promoting tumor cell survival. Inhibiting Chk2 in combination with DNA-damaging agents may provide a rational approach for treating resistant tumors.</p>
dc.identifier.submissionpathoapubs/343
dc.contributor.departmentDepartment of Molecular Genetics and Microbiology
dc.contributor.departmentDepartment of Cancer Biology
dc.source.pages11576-9


Files in this item

Thumbnail
Name:
17178848.pdf
Size:
286.5Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record